| Literature DB >> 32904079 |
Yuta Sato1, Keiichi Jingu1, Rei Umezawa1, Takaya Yamamoto1, Yojiro Ishikawa1, Kazuya Takeda1, Yu Suzuki1, Haruo Matsushita1.
Abstract
A 56-year-old male with stage IIIA (UICC 7th) non-small cell lung cancer (adenocarcinoma) received radiotherapy with 66 Gy/33 fractions concomitant with CBDCA and PTX. A partial response was achieved after chemoradiotherapy and the tumor continued to shrink over a period of 1 year; however, regrowth of the tumor attached to the aortic arch was observed without any other residual tumor or metastases. We diagnosed recurrence with slightly increased 18F-FDG uptake (maximum standardized uptake value: 12.2). Stereotactic radiotherapy was performed for the relapsed lesion with 60 Gy/10 fractions. The patient has survived for more than 5 years after stereotactic radiotherapy without recurrence or metastases, although he has been suffering from chest pain that has required treatment with a low dose of oxycodone. © The Japan Society of Clinical Oncology 2020.Entities:
Keywords: Definitive chemoradiotherapy; Non-small cell lung cancer; Salvage stereotactic radiotherapy
Year: 2020 PMID: 32904079 PMCID: PMC7450021 DOI: 10.1007/s13691-020-00431-5
Source DB: PubMed Journal: Int Cancer Conf J ISSN: 2192-3183